profit from every $100 of sales.
$0$100
Biodexa Pharmaceuticals
$2.38-0.83% today
-99.4% in 1 year
1-year low $2.381-year high $704.00
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2023.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Biodexa Pharmaceuticals sold, what it kept, and what it did with the cash.
Sales went from £699,000 in 2022 to £0 in 2025, with -£6.38 million of profit last year.
SalesProfit
Biodexa Pharmaceuticals vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Biodexa Pharmaceuticals | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Biodexa Pharmaceuticals's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 0 | 0 | 0 | |
| -4 | -4 | -5 | -4 | |
| -9 | -8 | -9 | -9 | |
| -8 | -7 | -6 | -6 | |
| -8 | -7 | -6 | -6 | |
| -775,000.00 | -10,000.00 | -500.00 | -0.50 | |
| -631.2% | -967.5% | – | – | |
| -1,277.8% | -2,103.4% | – | – | |
| -1,095.3% | -1,858.0% | – | – |
Balance sheet
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 6 | 11 | 15 | 18 |
| Cash | 3 | 6 | 2 | 9 |
| Total debt | 1 | 0 | 1 | 0 |
| Total liabilities | 2 | 6 | 6 | 7 |
| 3 | 5 | 8 | 11 | |
| 0 | 0 | 0 | 0 | |
| -176.0% | -114.4% | -50.8% | -43.1% | |
| -242.1% | -151.3% | -68.8% | -56.0% |
Cash flow
| In millions of GBP | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -7 | -7 | -12 | -6 | |
| 0 | 0 | 1 | 1 | |
| -7 | -7 | -13 | -6 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| – | – | – | – | |
| 0 | 0 | 0 | 0 |
Valuation
- –
- –
- –
- 0.1×
- 2.5×
- –
- –
- -752.1%
- -751.0%
- 0.0%
Profitability
- -967.5%
- -2,103.4%
- -1,858.0%
- 0.0%
- -72.3%
- -101.3%
- -55.8%
- -35.1%
- -72.7%
- –
Growth
- −45.5%
- –
- +58.6%
- –
- +1,430.4%
Financial health
- -0.8×
- 0.01
- 0.3%
- -72.3×
- 2.03
- 2.03
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 952
Bottom 1%of 870
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Mar 27, 2026 | -0.00 | -0.01 | +91.4% |
| Sep 12, 2025 | -0.00 | -0.00 | +93.2% |
| Apr 11, 2025 | -0.01 | -0.01 | −5.2% |
| Sep 26, 2024 | -0.33 | -0.22 | −49.8% |
| Apr 19, 2024 | -3.54 | -3.54 | −0.1% |
| Sep 15, 2023 | -2,773.25 | – | – |
| Apr 28, 2023 | -36,466.51 | – | – |
| Sep 14, 2022 | -23,986.03 | – | – |
News
Biodexa Pharmaceuticals reports 1H resultsSeeking Alpha · Sep 11, 2026The newest story we have is from Sep 11, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
70Pass
Philip Fisher
36No pass
Peter Lynch
40No pass
Joel Greenblatt
0No pass
Charlie Munger
48No pass
Terry Smith
38No pass
Questions about Biodexa Pharmaceuticals
Is Biodexa Pharmaceuticals a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Biodexa Pharmaceuticals AI analysis
What does Biodexa Pharmaceuticals do?
Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. It is in Biotechnology.
Does Biodexa Pharmaceuticals pay a dividend?
No. Biodexa Pharmaceuticals does not pay a dividend at the moment.
Is Biodexa Pharmaceuticals stock halal?
No. Biodexa Pharmaceuticals does not pass our halal screen: its cash and confirmed interest-bearing investments are 905% of its market value, at or above the 33% limit. How we check
How has Biodexa Pharmaceuticals stock done over the past year?
Down 99.4% over the past twelve months, to $2.38. It traded between $2.38 and $704.00 and is 99.7% below its high.
Who are Biodexa Pharmaceuticals's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Biodexa Pharmaceuticals's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.